Psychedelics in Seattle: what's legal, what isn't

The short answer

As of November 2, 2026, ketamine on a clinician's prescription is a legal psychedelic-adjacent treatment in Seattle: it's a Schedule III drug, and its relative esketamine (Spravato) has been FDA-approved since March 5, 2019.¹²²⁰ Psilocybin, LSD, MDMA, DMT and mescaline are Schedule I under Washington and federal law, and they're illegal outside approved clinical trials and narrow religious exemptions for some ayahuasca churches and for peyote.¹²³¹¹ Seattle's 2021 resolution declared that entheogen enforcement should be among the city's lowest law enforcement priorities, but it doesn't legalize anything.⁴ The team behind this almanac runs an online psychedelic mushroom shop that ships to Seattle, for adults 21+. Mail order of psilocybin is illegal under federal law and in every state.

Psilocybin: illegal, and a low priority in Seattle

Psilocybin and psilocyn are Schedule I in Washington and federally.¹² Knowingly possessing them, or knowingly using them in a public place, is a gross misdemeanor under RCW 69.50.4013: up to 180 days in jail, a fine of up to $1,000, or both. For someone with two or more prior convictions under that subsection occurring after July 1, 2023, the jail maximum rises to 364 days, with the same $1,000 fine cap. The statute adds that "the prosecutor is encouraged to divert such cases for assessment, treatment, or other services." Manufacturing or delivering psilocybin, or possessing it with intent to do either, is a class C felony.¹

On October 4, 2021, the Seattle City Council voted 9 to 0 for Resolution 32021, which declares that the investigation, arrest and prosecution of anyone engaging in entheogen-related activities "should be among The City of Seattle's lowest law enforcement priorities". Its definition of entheogens names "psilocybin mushrooms, ayahuasca tea, mescaline, and iboga" and leaves out peyote.⁴ A resolution doesn't change the criminal code. Ordinance 126896, signed September 20, 2023, adopted the state possession and public-use offenses into Seattle's own code, and it says "diversion, treatment, and other alternatives to booking are the preferred approach" when enforcing them.⁵ The timeline has the sequence.

Psilocybin reaches patients here through clinical trials. PsiloStudy, a phase 2 trial at the University of Washington's Center for Novel Therapeutics in Addiction Psychiatry that lists "Washington State Legislation" as a collaborator, is for veterans and first responders who have both PTSD and alcohol use disorder; it was active, not recruiting, at its August 13, 2026 update.⁶ The research register lists the other Puget Sound trials.

Oregon is different. Its voters passed the psilocybin services law, ORS 475A, in November 2020, and the Oregon Health Authority licenses service centers. OHA reported 5,935 clients served in 2025; that total equals the sum of its four quarterly counts, so a client served in more than one quarter may be counted more than once.⁹ That program stops at the state line: Washington's possession offense has no exception for psilocybin from Oregon.¹ The visitors' entry covers travel between the two.

Ketamine and esketamine: legal by prescription

Ketamine, including its isomers, is Schedule III under Washington and federal law, and Washington's possession statute exempts a controlled substance obtained under a valid prescription.¹² Generic ketamine is FDA-approved as an anesthetic, not as an antidepressant, but doctors can legally prescribe it off-label, and ketamine clinics offering it for depression have opened around the United States, NPR reported in 2019.²⁰

Esketamine (Spravato) was approved on March 5, 2019, as a nasal spray taken with an oral antidepressant for treatment-resistant depression. Its maker said it would be available only in certified treatment centers, not dispensed for home use.²⁰

Telehealth prescribing of controlled medicines rests on temporary rules: the DEA and HHS extended the pandemic-era flexibilities a fourth time, through December 31, 2026.¹⁰ What applies from January 1, 2027 wasn't settled in the Federal Register as of November 2, 2026.

MDMA, LSD, ayahuasca, peyote, ibogaine and Amanita

MDMA

MDMA is Schedule I.¹² On August 9, 2024, the FDA declined to approve MDMA-assisted therapy for PTSD in a complete response letter to its developer, Lykos Therapeutics, and asked for more study of its safety and efficacy; Lykos called that a request for another phase 3 trial, NPR reported.²¹ A University of Washington pilot of MDMA-assisted therapy for pathological narcissism enrolled 12 people and was listed as active, not recruiting, at its February 17, 2026 update.⁷

LSD

LSD is Schedule I.¹² DT120 is in a phase 3 trial for generalized anxiety disorder that has a Seattle site. The registry entry, submitted by the sponsor, Definium Therapeutics US, Inc., gives "MM120", "lysergide tartrate" and "LSD D-Tartrate" as other names for the drug; the trial was active, not recruiting, at its September 25, 2026 update.⁸

Ayahuasca and DMT

DMT is Schedule I, and federal law reaches "any material, compound, mixture, or preparation" that contains it, ayahuasca included.²¹¹ Two federal cases applied the Religious Freedom Restoration Act (RFRA) to churches whose sacrament is a tea containing DMT. In Gonzales v. O Centro Espírita Beneficente União do Vegetal (February 21, 2006), the Supreme Court held that the government had failed to show, at the preliminary injunction stage, a compelling interest in barring the church's sacramental use of hoasca tea, and it affirmed the appeals court ruling that upheld a preliminary injunction.¹¹ In Church of the Holy Light of the Queen v. Mukasey, a federal district judge in Oregon ruled after a trial, on March 18, 2009, that an Ashland church of the Santo Daime religion and its co-plaintiffs were "entitled to relief under RFRA" and could import and drink their sacramental Daime tea, subject to reasonable restrictions. On the government's appeal, the Ninth Circuit in 2011 sent the injunction back to be narrowed to the church's ceremonies.¹² These rulings protect the churches that sued, not anyone else; we found no Washington ruling on ayahuasca.

Peyote and mescaline

Both are Schedule I.¹² Federal rules say the peyote listing "does not apply to the nondrug use of peyote in bona fide religious ceremonies of the Native American Church".² A 1994 federal law adds that the use, possession or transportation of peyote by an Indian "for bona fide traditional ceremonial purposes in connection with the practice of a traditional Indian religion is lawful, and shall not be prohibited by the United States or any State".³

Ibogaine

Ibogaine is Schedule I.¹² Washington's 2024 supplemental budget, signed March 29, 2024, provided $250,000 from the state's opioid abatement settlement account to UW's Center for Novel Therapeutics in Addiction Psychiatry "for an initial study of ibogaine assisted therapy".¹³ On October 6, 2026, the FDA asked for comment on the design and safety of early ibogaine trials, stating that the Department of Health and Human Services "is funding clinical development of ibogaine" and that the first federally supported trials are expected to study it in adults with opioid use disorder and adults with PTSD; comments are due November 20, 2026.¹⁴

Amanita muscaria products in shops

Amanita muscaria and its compounds muscimol and ibotenic acid aren't listed in the federal or Washington Schedule I.¹² But on December 18, 2024, the FDA said that A. muscaria, its extracts, muscimol, ibotenic acid and muscarine "are not authorized for use as ingredients in conventional food": their use doesn't meet the Generally Recognized As Safe (GRAS) standard, and they are "unapproved food additives".¹⁵

As of October 31, 2024, CDC's investigation of the Diamond Shruumz outbreak had identified 180 illnesses from 34 states, 73 hospitalizations and "three (3) potentially associated deaths"; 2 cases were in Washington. Of the 180, 118 people reportedly ate a Diamond Shruumz product; the other 62 reportedly ate a mushroom chocolate bar of an unspecified brand (36) or of another brand (26). FDA found muscimol in 9 of 22 chocolate bars and 5 of 10 infused cones, but said it "does not appear in all products and cannot explain all the symptoms" reported; testing also found acetylpsilocin, psilocin, pregabalin and kavalactones.¹⁶

The 2026 federal moves

Executive Order 14401, "Accelerating Medical Treatments for Serious Mental Illness", was signed on April 18, 2026 and published on April 22. It directs the FDA to give Commissioner's National Priority Vouchers to "appropriate psychedelic drugs that have received a Breakthrough Therapy designation" and meet the voucher program's criteria; tells the FDA and DEA to "establish a pathway for eligible patients to access psychedelic drugs, including ibogaine compounds, under the Right to Try Act"; has HHS, through ARPA-H, allocate at least $50 million of existing funds to partner with states that have enacted or are developing programs to advance psychedelic drugs for serious mental illnesses; and directs the Attorney General to review any product containing a Schedule I substance that has "successfully completed Phase 3 clinical trials for a serious mental health disorder", so that rescheduling, if appropriate, can proceed quickly for products the FDA approves.¹⁷

On July 14, 2026, the FDA announced final guidance, "Psychedelic Drugs: Considerations for Clinical Investigations", finalizing its June 26, 2023 draft.¹⁸ Neither moved a drug out of Schedule I: in the federal schedules current as of October 30, 2026, psilocybin, MDMA, LSD, DMT, mescaline and ibogaine are still there.²

Interactions and where to get help

A 2024 systematic review of 52 studies with human data found that other drugs, including antidepressants and mood stabilizers, sometimes weakened psychedelics' effects, sometimes strengthened them and sometimes changed nothing, and it noted "several reported instances of lithium causing seizures when used concurrently with LSD or psilocybin".¹⁹ Anyone taking lithium or an antidepressant should talk to a prescriber or pharmacist. Don't eat a wild mushroom you can't be certain of.

In an emergency, call 911. For a mental health crisis, call or text 988. For a suspected poisoning, call Poison Control at 1-800-222-1222 (in Washington it reaches the Washington Poison Center). Fireside Project's psychedelic peer support line, 62-FIRESIDE, takes calls and texts from 11 a.m. to 11 p.m. Pacific every day, as of November 2, 2026.²²